Dehua Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dehua Huang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Baochun Zhou
1 shared publicationChunyan Li
Suzhou Institute of Nano‐Tech and Nano‐Bionics Chinese Academy of Sciences Suzhou 215123 China
1 shared publication- Dandan Liang
School of Chinese Language and Literature, Nanjing Normal University, Jiangsu, China
1 shared publication - Guangcun Chen
Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences
1 shared publication Haiwei Sun
1 shared publicationJiaman Ou
Department of Cardiology, People's Hospital of Yangjiang, Yangjiang, China
1 shared publication
Latest Publications
- Open Access
- 9 March 2026
- Published by Elsevier in SSRN Electronic Journal
Dexmedetomidine attenuates neuronal injury after stroke ischaemia‐reperfusion injury by targeting REDD1 to reduce excessive autophagy
Background: Ischemic stroke, accounting for approximately 87% of stroke cases, often leads to severe neurological impairment due to ischemia/reperfusion (I/R) injury. While dexmedetomidine (Dex) has shown potential neuroprotective effects, its precise mechanisms remain unclear. This study investigated whether Dex attenuates cerebral I/R injury by regulating REDD1-mediated autophagy.Methods: Using a rat model of middle cerebral artery occlusion (MCAO) and an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) model in HT22 cells, we evaluated the effects of Dex on neurological function, infarct volume, and autophagy activity.Results: Dex treatment significantly improved neurological scores, reduced cerebral infarct volume, and ameliorated neuronal damage in MCAO rats. In HT22 cells, Dex enhanced cell viability under OGD/R conditions and suppressed excessive autophagy, as evidenced by decreased LC3-II and increased p62 expression. Mechanistically, Dex upregulated REDD1 expression, and molecular docking confirmed direct binding between Dex and REDD1. HuProt microarray analysis further validated REDD1 as a key target. Crucially, REDD1 knockdown abolished Dex-mediated autophagy inhibition and neuroprotection.Conclusions: These findings demonstrate that Dex alleviates cerebral I/R injury by targeting REDD1 to reduce excessive autophagy, providing novel insights into its therapeutic potential for ischemic stroke.
- 9 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDexmedetomidine attenuates neuronal injury after stroke ischaemia‐reperfusion injury by targeting REDD1 to reduce excessive autophagy
Background: Ischemic stroke, accounting for approximately 87% of stroke cases, often leads to severe neurological impairment due to ischemia/reperfusion (I/R) injury. While dexmedetomidine (Dex) has shown potential neuroprotective effects, its precise mechanisms remain unclear. This study investigated whether Dex attenuates cerebral I/R injury by regulating REDD1-mediated autophagy.Methods: Using a rat model of middle cerebral artery occlusion (MCAO) and an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) model in HT22 cells, we evaluated the effects of Dex on neurological function, infarct volume, and autophagy activity.Results: Dex treatment significantly improved neurological scores, reduced cerebral infarct volume, and ameliorated neuronal damage in MCAO rats. In HT22 cells, Dex enhanced cell viability under OGD/R conditions and suppressed excessive autophagy, as evidenced by decreased LC3-II and increased p62 expression. Mechanistically, Dex upregulated REDD1 expression, and molecular docking confirmed direct binding between Dex and REDD1. HuProt microarray analysis further validated REDD1 as a key target. Crucially, REDD1 knockdown abolished Dex-mediated autophagy inhibition and neuroprotection.Conclusions: These findings demonstrate that Dex alleviates cerebral I/R injury by targeting REDD1 to reduce excessive autophagy, providing novel insights into its therapeutic potential for ischemic stroke.
- Open Access
- 17 July 2025
- Published by Wiley in ChemistryEurope
- Vol. 3 (6)
A Poly ( β ‐Amino Esters)‐Based Multicomponent Nanoparticle for Efficient mRNA Delivery to Acute Myeloid Leukemia Cells
Gene delivery to acute myeloid leukemia (AML) cells is crucial for mechanistic studies and targeted therapeutics, yet nonviral transfection methods remain limited by low cellular uptake and inefficient endosomal escape in suspension AML cells. Herein, a rationally designed multicomponent nanoparticle comprising a poly( β ‐amino ester) polymer core for robust nucleic acid complexation, palmitic anhydride to enhance cellular internalization, and the cationic lipid 1,2‐Dioleoyl‐3‐trimethylammonium‐propane to facilitate efficient endosomal escape is presented. Systematic optimization of these components yields nanoparticles with outstanding transfection efficiency (up to 64.4%) and minimal cytotoxicity in suspension AML cells (MOLM13). Utilizing red firefly luciferase‐mRNA as a reporter, rapid and specific enrichment of transfected MOLM13 cells in the pelvic region of mice following intravenous injection is demonstrated. This advanced nanoparticle platform significantly enhances gene delivery to suspension AML cells, promising new avenues for AML research and therapeutic interventions.
- 17 July 2025
- Published by Wiley in ChemistryEurope
- Vol. 3 (6)
Open AccessA Poly ( β ‐Amino Esters)‐Based Multicomponent Nanoparticle for Efficient mRNA Delivery to Acute Myeloid Leukemia Cells
Gene delivery to acute myeloid leukemia (AML) cells is crucial for mechanistic studies and targeted therapeutics, yet nonviral transfection methods remain limited by low cellular uptake and inefficient endosomal escape in suspension AML cells. Herein, a rationally designed multicomponent nanoparticle comprising a poly( β ‐amino ester) polymer core for robust nucleic acid complexation, palmitic anhydride to enhance cellular internalization, and the cationic lipid 1,2‐Dioleoyl‐3‐trimethylammonium‐propane to facilitate efficient endosomal escape is presented. Systematic optimization of these components yields nanoparticles with outstanding transfection efficiency (up to 64.4%) and minimal cytotoxicity in suspension AML cells (MOLM13). Utilizing red firefly luciferase‐mRNA as a reporter, rapid and specific enrichment of transfected MOLM13 cells in the pelvic region of mice following intravenous injection is demonstrated. This advanced nanoparticle platform significantly enhances gene delivery to suspension AML cells, promising new avenues for AML research and therapeutic interventions.
- Open Access
- 22 June 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 858889
The U-Shaped Relationship Between Serum Uric Acid and Long-Term All-Cause Mortality in Coronary Artery Disease Patients: A Cohort Study of 33,034 Patients
Background: Associations between high serum uric acid (SUA) and cardiovascular diseases have been reported. However, few studies have been conducted to explore the relationship between SUA and long-term all-cause mortality in coronary artery disease (CAD) patients. Our study aims to investigate the relationship between SUA and long-term all-cause mortality in patients with CAD.Methods: From January 2007 to December 2018, we divided 33,034 patients with CAD admitted in the Guangdong Provincial People's Hospital into five groups (quintile 1: SUA CI: 1.01–1.26, p = 0.03), and SUA ≥8 mg/dL (aHR = 1.18, 95% CI: 1.06-1.32, p = 0.003).Conclusion: Our study indicated a U-shaped relationship between SUA and long-term all-cause mortality in patients with CAD. No matter whether SUA is too high or too low, it increased the all-cause mortality in the CAD population, which deserves to be closely monitored.
- 22 June 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 858889
Open AccessThe U-Shaped Relationship Between Serum Uric Acid and Long-Term All-Cause Mortality in Coronary Artery Disease Patients: A Cohort Study of 33,034 Patients
Background: Associations between high serum uric acid (SUA) and cardiovascular diseases have been reported. However, few studies have been conducted to explore the relationship between SUA and long-term all-cause mortality in coronary artery disease (CAD) patients. Our study aims to investigate the relationship between SUA and long-term all-cause mortality in patients with CAD.Methods: From January 2007 to December 2018, we divided 33,034 patients with CAD admitted in the Guangdong Provincial People's Hospital into five groups (quintile 1: SUA CI: 1.01–1.26, p = 0.03), and SUA ≥8 mg/dL (aHR = 1.18, 95% CI: 1.06-1.32, p = 0.003).Conclusion: Our study indicated a U-shaped relationship between SUA and long-term all-cause mortality in patients with CAD. No matter whether SUA is too high or too low, it increased the all-cause mortality in the CAD population, which deserves to be closely monitored.